RecallRadar

FDA Drug recall D-0018-2019

treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectable suspension

On 2018-10-10 the FDA classified a Class III recall of treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectable suspension by Otsuka Pharmaceutical Development And Commercialization, citing labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of k….

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0018-2019
ClassificationClass III
Statusterminated
Initiated2018-09-17
Published2018-10-10
Last updated2026-09-13 11:52 UTC
CompanyOtsuka Pharmaceutical Development And Commercialization
DistributionUS

Product

treatNOW ABILIFY (aripiprazole) / ABILIFY MAINTENA 400-mg (aripiprazole) for extended release injectable suspension. Kit contents 2 packs Abilify Tablets 10 mg (14 day supply) plus 1 Abilfy Maintena Vial Kit.Rx only. Distributed and Marketed by: Otsuka America Pharmaceutical, Inc. Rockville, MD 20850 USA Marketed by: Lundbleck, Deerfield, IL 60015 USA Bar Code VialKit-59148-10Tabs-02

Reason

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Identifiers

code_infoLots: 7F92YUD3H1A/ACS1616B, EXP 31-Jul-2019; F92YUD3H1A/ACS0118C, EXP 30-Jun-2020.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0018-2019%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.